JM
Johnny Mahlangu
University of the Witwatersrand
Research areas: Medicine · Hematology · Hemophilia Treatment and Research · Platelet Disorders and Treatments · Coagulation, Bradykinin, Polyphosphates, and Angioedema
0000-0001-5781-7669
Employment
-
University of the Witwatersrand Professor
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (334)
- Recombinant activated factor VIIa for severe postpartum hemorrhage in Africa: Evidence, appropriate use, and research priorities—A narrative review Save
- An evaluation of denecimig for bleeding prophylaxis in hemophilia A Save
- Future management of hemophilia A with non-biologic hemostatic agents: a call for precision coagulation Save
- Advances in treatments for hemophilia A/B with inhibitors: current treatment gaps and promising therapies Save
- A bayesian model selection framework for capital allocation and predictive financial analytics Save
- Denecimig (Mim8) prophylaxis in children with hemophilia A with or without factor VIII inhibitors Save
- Futuristic global cell and gene therapy regulations based on a review of today’s leading frameworks Save
- Molecular diagnosis of hemophilia in the era of advanced genomic technology: current status and future in Africa Save
- A revised classification of FVIII concentrates: rationale and novel metrics Save
- The MAPTO survey: worldwide approaches on unmasking factor VIII inhibitors in children with emicizumab treatment: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders Save
- Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors Save
- Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study Save
- Is marstacimab the next step in personalized and effective haemophilia management? Save
- Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial Save
- A comprehensive care pathway of gene therapy for hemophilia based on current guideline documents and summary of product characteristics: communication from the ISTH SSC working group on gene therapy Save
- The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025 Save
- A Bayesian Model Selection Framework for Capital Allocation and Predictive Financial Analytics Save
- A Systematic Review and Meta-Analysis of Genomic Variations of Haemophilia A and B: the Case for Personalized Medicine Save
- Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial Save
- The diffuse large B-cell lymphoma disease profile at Charlotte Maxeke Johannesburg Academic Hospital from July 2020 to June 2022 Save